Clinical biomarkers are crucial measurable indicators used in healthcare and medical research to assess various physiological or pathological processes in the body. They provide valuable insights into health status, disease progression, treatment response, and overall well-being. Biomarkers encompass proteins, nucleic acids, metabolites, hormones, and cellular or tissue characteristics.
The global clinical biomarkers market is witnessing significant growth due to increased product and service usage, key player initiatives, and government support. Factors driving this growth include healthcare companies' investments to meet industry demand and the adoption of biomarkers in drug discovery, disease risk assessment, and other applications.
Recent developments include Abbott Laboratories' Alinity i Lab-Based Blood Test for mild traumatic brain injury assessment and Illumina Inc.'s TruSight Oncology 500 ctDNA v2 for comprehensive genomic profiling of circulating tumor DNA.
BIS Research released the Global Clinical Biomarkers Market Report, which covers 2023 to 2033, with a base year of 2022. The market size 2023 was $24.80 billion, with a projected value of $53.20 billion by 2033, reflecting a CAGR of 7.93%. The report spans 255 pages and includes 21 tables and 186 figures.
Click Here to Download a Free Sample
The global clinical biomarkers market is driven by increasing demand for advanced products spurred by rising cancer cases worldwide. Key players are adapting technologies to meet market needs, particularly in response to growing cancer incidence rates and the healthcare industry's focus on effective diagnostics. However, challenges arise from the high cost of products and services, limiting adoption in low-income countries due to significant capital investment requirements. Depending on laboratory scale and capabilities, expensive instruments contribute to the substantial capital needed.
Despite immense market potential, these investment demands hinder global market expansion. Yet, opportunities lie in technological advancements in biomarker testing, with methods like ELISA, gel electrophoresis, SPR, BioCD protein arrays, SERS, colorimetric, electrochemical assays, and fluorescence techniques offering precise detection capabilities. These advancements enhance diagnostic precision, potentially expanding market reach and addressing global healthcare challenges in cancer detection and treatment.
The clinical biomarkers market is segmented across various dimensions. In terms of offering, it encompasses products and services, with products like efficacy, safety, and validation biomarkers and services, including genomic, tissue, and cell services.
The product sector led the market in 2022, with significant investments from key players to drive future growth. Cancer biomarkers are projected to experience the highest growth within clinical areas, covering genetic and protein biomarkers like BRCA1/BRCA2 and EGFR, alongside areas like cardiac, neurological, infectious diseases, immunological, and non-invasive prenatal testing.
Technology-wise, next-generation sequencing (NGS) facilitates the simultaneous evaluation of multiple malignancy genes, followed by PCR, IHC, ELISA, and others. End users range from contract research organizations (CROs) to research labs, biopharmaceutical companies, and diagnostic centers, with CROs witnessing notable growth as providers of biomarker testing services for the pharmaceutical and biotech industries.
Geographically, North America leads, particularly the U.S. and Canada, followed by Europe, Asia-Pacific, Latin America, and the rest of the world, encompassing countries such as Japan, India, China, Brazil, and Mexico.
Some of the prominent names profiled in the clinical biomarkers market report include:
• Abbott Laboratories
• Agilent Technologies, Inc.
• ALCEN
• Arsenal Capital Partners
• Azenta Life Sciences
• Becton, Dickinson and Company
• BGI
• bioMérieux S.A.
• Bio-Rad Laboratories, Inc.
• Broad Institute
• Caris Life Sciences
• CENTOGENE N.V.
• Charles River Laboratories
• Discovery Life Sciences (DLS)
• Enzo Biochem Inc.
• Eurofins Scientific
• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• Myriad Genetics, Inc.
• NeoGenomics Laboratories
• Novogene Co., Ltd.
• Personalis Inc.
• Q² Solutions
• QIAGEN N.V.
• Quest Diagnostics Incorporated
• Thermo Fisher Scientific Inc.
The Clinical Biomarkers Market Report offers unique selling points (USPs), such as an in-depth competitive analysis of 26 major players, providing a comprehensive overview of the clinical biomarkers market. It examines the market's economic influence and highlights notable end-user industry advancements. The report conducts a thorough supply chain and pricing analysis. It also delves into the investment landscape, assessing product adoption trends and patents. These features make the report valuable for understanding the market's dynamics and opportunities.
BIS principal analyst: Existing players in the clinical biomarkers industry are implementing diverse strategies to strengthen their market presence. These strategies include integrating artificial intelligence into biomarker discovery, expanding biomarker usage in precision medicine, and advancing technologies in clinical biomarker diagnosis. The comprehensive analysis provided in the global clinical biomarkers report offers valuable insights for manufacturers, service providers, and end users, enabling informed decision-making, targeted marketing, strategic planning, product benchmarking, and optimized resource allocation.
Interested to know more about the growing technologies in your industry vertical? Get the latest market studies and insights from BIS Research. Connect with us at [email protected] to learn and understand more.
